Evaluation of Block Duration in Type 2 Diabetes Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Diabetes Type 2
Interventions
DRUG

ropivacaine

patients received 20 mL ropivacaine 5 mg/mL on subgluteal nerve

Trial Locations (1)

75013

APHP Pitié-Sampetriere, Paris

All Listed Sponsors
collaborator

Centre Hospitalier Universitaire de Nīmes

OTHER

lead

Pierre and Marie Curie University

OTHER

NCT01704612 - Evaluation of Block Duration in Type 2 Diabetes Patients | Biotech Hunter | Biotech Hunter